Drug Profile
DNX 2440
Alternative Names: Delta-24-RGDOX; DNX-2440Latest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer DNAtrix; University of Navarra
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma; Liver metastases
Most Recent Events
- 11 Apr 2023 Phase-I development is ongoing in Glioblastoma (Recurrent) in Spain (Intratumoural, Injection) (DNAtrix pipeline, April 2023)
- 05 Apr 2023 Clinica Universidad de Navarra terminates a phase I trial in Glioblastoma (Recurrent) in Spain due to break of stock (Intertumoral)(NCT03714334)
- 11 Apr 2022 Pharmacodynamics data from preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)